Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan F List

Showing results (181-190 of 212) with videos related to

Pageof 22
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|September 18, 2013
TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patientsGisela Caceres, Kathy McGraw, Bon Ham Yip, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2021
Integrated Human and Murine Clinical Study Establishes Clinical Efficacy of Ruxolitinib in Chronic Myelomonocytic LeukemiaAnthony M Hunter, Hannah Newman, Amy E Dezern, et al.
Blood|September 26, 2007
Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5qAzra Raza, James A Reeves, Eric J Feldman, et al.
The Lancet. Haematology|August 4, 2018
Assessment of ASC specks as a putative biomarker of pyroptosis in myelodysplastic syndromes: an observational cohort studyAshley A Basiorka, Kathy L McGraw, Farnoosh Abbas-Aghababazadeh, et al.
Blood|October 15, 2016
The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotypeAshley A Basiorka, Kathy L McGraw, Erika A Eksioglu, et al.
International Journal of Molecular Sciences|February 25, 2023
Oxidized Mitochondrial DNA Engages TLR9 to Activate the NLRP3 Inflammasome in Myelodysplastic SyndromesGrace A Ward, Robert P Dalton, Benjamin S Meyer, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 19, 2015
Reduced DOCK4 expression leads to erythroid dysplasia in myelodysplastic syndromesSriram Sundaravel, Ryan Duggan, Tushar Bhagat, et al.
British Journal of Haematology|July 9, 2013
A model for prediction of FLT3-ITD and NPM1 (without FLT3-ITD) positivity in patients with newly diagnosed acute myeloid leukaemiaFabiana Ostronoff, Megan Othus, Hagop M Kantarjian, et al.
Blood|January 28, 2015
An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adultsMichael R Savona, Luca Malcovati, Rami Komrokji, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 10, 2017
Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117Mikkael A Sekeres, Megan Othus, Alan F List, et al.
Pageof 22

Showing results (181-190 of 212) with videos related to

Sort By:
Pageof 22
Proceedings of the National Academy of Sciences of the United States of America|September 18, 2013
TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patientsGisela Caceres, Kathy McGraw, Bon Ham Yip, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2021
Integrated Human and Murine Clinical Study Establishes Clinical Efficacy of Ruxolitinib in Chronic Myelomonocytic LeukemiaAnthony M Hunter, Hannah Newman, Amy E Dezern, et al.
Blood|September 26, 2007
Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5qAzra Raza, James A Reeves, Eric J Feldman, et al.
The Lancet. Haematology|August 4, 2018
Assessment of ASC specks as a putative biomarker of pyroptosis in myelodysplastic syndromes: an observational cohort studyAshley A Basiorka, Kathy L McGraw, Farnoosh Abbas-Aghababazadeh, et al.
Blood|October 15, 2016
The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotypeAshley A Basiorka, Kathy L McGraw, Erika A Eksioglu, et al.
International Journal of Molecular Sciences|February 25, 2023
Oxidized Mitochondrial DNA Engages TLR9 to Activate the NLRP3 Inflammasome in Myelodysplastic SyndromesGrace A Ward, Robert P Dalton, Benjamin S Meyer, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 19, 2015
Reduced DOCK4 expression leads to erythroid dysplasia in myelodysplastic syndromesSriram Sundaravel, Ryan Duggan, Tushar Bhagat, et al.
British Journal of Haematology|July 9, 2013
A model for prediction of FLT3-ITD and NPM1 (without FLT3-ITD) positivity in patients with newly diagnosed acute myeloid leukaemiaFabiana Ostronoff, Megan Othus, Hagop M Kantarjian, et al.
Blood|January 28, 2015
An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adultsMichael R Savona, Luca Malcovati, Rami Komrokji, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 10, 2017
Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117Mikkael A Sekeres, Megan Othus, Alan F List, et al.
Pageof 22